Affiliation:
1. Novartis Pharma AG Basel Switzerland
2. Pharmacoepidemiology Group Institute of Pharmaceutical Sciences, ETH Zurich Zurich Switzerland
3. Leslie Dan Faculty of Pharmacy University of Toronto Toronto Ontario Canada
4. Eli Lilly and Company Indianapolis Indiana USA
5. Departments of Oncology and of Biostatistics, Bioinformatics, and Biomathematics, Lombardi Comprehensive Cancer Center and Innovation Center for Biomedical Informatics Georgetown University Medical Center Washington DC USA
Abstract
The decentralized clinical trial (DCT) approach is increasingly recognized as a means to accelerate the development of potential therapeutic interventions. DCTs have a crucial advantage over traditional clinical trials: patients are monitored in their environment using technology (e.g., wearables), that capture data as they continue in daily life. This narrative review outlines a gap analysis focused on the frameworks and guidance from expert working groups and regulatory agencies for the design and execution of DCTs. Eight DCT elements guided the analysis and summarized the frameworks and guidance: (1) suitability, (2) protocol, (3) investigational medicinal product (IMP) supply, (4) investigators and health care providers, (5) safety, (6) regulatory and ethics, (7) data and technology, and (8) engagement, communication, and advocacy. Based on the gap analysis, two key takeaways were identified: (1) a need for a comprehensive sustainability assessment of each DCT element; and (2) current frameworks and guidance provide recommendations on social sustainability and some on economic sustainability. DCTs are an essential evolution in healthcare research; however, more guidance related to a comprehensive assessment of designing and executing sustainable DCTs is needed. This is especially the case for environmental sustainability, including, for example, carbon footprint and disposal of IMPs and sensors.
Subject
Pharmacology (medical),Pharmacology
Reference26 articles.
1. Decentralised, patient-centric, site-less, virtual, and digital clinical trials? From confusion to consensus
2. Opportunities and Challenges for Decentralized Clinical Trials: European Regulators’ Perspective
3. Burrows A.Decentralized and hybrid clinical trials report 2020.Inf. Connect (2020). Accessed July 16 2022.
4. The impact of decentralized and hybrid trials on sponsor and CRO collaborations;Diamond P.;Appl. Clin. Trials Online,2021
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献